US stock futures steady after Wall St soars on dovish Powell; Nvidia earnings due
LAVAL, Quebec - Bausch Health, Canada Inc. (NYSE:BHC)(TSX:BHC), a prominent player in the pharmaceuticals industry with a robust 70.7% gross profit margin and strong revenue growth of 7.13% over the last twelve months, announced Thursday that its triple-combination acne treatment CABTREO is now available to beneficiaries of public drug plans in Quebec and Saskatchewan. According to InvestingPro analysis, the company’s solid financial health and market position suggest potential for continued growth.
The prescription gel, which combines clindamycin phosphate, adapalene and benzoyl peroxide, was previously made available last month to patients covered by public drug plans in Ontario and Nova Scotia, as well as through federal government plans including Non-Insured Health Benefits for Indigenous populations.
CABTREO is approved by Health Canada for treating acne vulgaris in patients 12 years and older. According to the company, it represents the first and only triple-combination topical treatment for acne approved in Canada that combines three mechanisms of action: an antibiotic, a retinoid and an antibacterial agent.
"The addition of CABTREO to the Quebec and Saskatchewan public drug plans means more Canadians now have access to this acne treatment," said Amy Cairns, General Manager of Bausch Health Canada, in the press release.
The treatment is administered once daily to affected areas of the skin. In clinical trials involving 363 patients with facial acne vulgaris, CABTREO achieved approximately 50% treatment success and over 70% reduction in both inflammatory and noninflammatory lesions at 12 weeks. The company’s strong market performance, with a 30.02% return over the past year, reflects investor confidence in its product pipeline. For deeper insights into Bausch Health’s growth potential and comprehensive financial analysis, investors can access detailed research reports on InvestingPro, which offers exclusive metrics and expert analysis for over 1,400 US stocks.
Common side effects reported include mild to moderate application site reactions such as scaling, dryness, redness, and burning or stinging. The product is not authorized for use in children under 12 years of age.
CABTREO is manufactured at Bausch Health’s facility in Laval, Quebec, and is the fourth new dermatology treatment from the company to receive Health Canada approval in the past four years. With an EBITDA of $3.11 billion and a market capitalization of $2.81 billion, Bausch Health continues to demonstrate strong operational execution. InvestingPro data reveals additional growth indicators and valuable insights available to subscribers.
Acne vulgaris affects approximately 5.6 million Canadians, including about 90% of adolescents, according to the Canadian Dermatology Association information cited in the company’s statement.
In other recent news, Bausch Health Companies Inc. reported its Q2 2025 earnings, highlighting a strong revenue performance. The company achieved earnings per share of $0.40, which significantly surpassed analyst forecasts of $0.04, resulting in a 900% surprise. Revenue for the quarter reached $2.53 billion, slightly exceeding expectations of $2.48 billion. Despite these positive earnings results, Bausch Health experienced a notable dip in its stock price. The stock fell 13.64% in after-hours trading. This development comes amidst ongoing market dynamics affecting the company. These recent financial results and market reactions are crucial for investors to consider.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.